MedTrace Logo

Orlistat Treatment of Crigler-Najjar Disease

NCT00461799 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2007-04-18

No results posted yet for this study

Summary

The purpose of this study was to determine whether orlistat is effective in decreasing plasma unconjugated bilirubin levels in patients with Crigler-Najjar disease.

Conditions

  • Crigler-Najjar Syndrome

Interventions

DRUG

orlistat

Sponsors & Collaborators

  • Erasmus Medical Center

    collaborator OTHER

  • De Najjar Stichting

    collaborator OTHER

  • University Medical Center Groningen

    lead OTHER

Principal Investigators

  • Anja M. Hafkamp, MD · University Medical Center Groningen and Erasmus University Medical Center

  • Maarten Sinaasappel, MD · Erasmus Medical Center

  • Henkjan J. Verkade, MD, PhD · University Medical Center Groningen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
8 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-09-30
Completion
2004-01-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00461799 on ClinicalTrials.gov